Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04683926 · ClinicalTrials.gov registry record · Phase 1
A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects
A Phase 1 study of Pain, sponsored by Syntrix Biosystems.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04683926: Completed Phase 1 study of Pain, sponsored by Syntrix Biosystems.
NCT04683926 is a Phase 1 study of Pain that has completed, run by Syntrix Biosystems. The registered enrollment target is 24 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04683926, a Phase 1 study of Pain, has completed, sponsored by Syntrix Biosystems.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to investigate in healthy human subjects how much desmetramadol (Omnitram) gets in the blood after different oral doses are taken with or without food.
Primary Outcome
The AUC(0-32) and AUC(inf) of (-/+)-M1 after each treatment (i.e., 10, 20 and 30 mg desmetramadol fasted, and 30 mg desmetramadol fed)
Conditions Studied
Interventions
- DRUG Desmetramadol
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-01-08 |
| Est. Completion | 2021-01-18 |
| Phase | Phase 1 |
What the finished NCT04683926 record still lists
NCT04683926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Desmetramadol is the first listed.
NCT04683926 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT04683926 about?
NCT04683926 is a clinical study titled "A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects". The purpose of the study is to investigate in healthy human subjects how much desmetramadol (Omnitram) gets in the blood after different oral doses are taken with or without food.
What is the current status of trial NCT04683926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-01-08. Estimated completion is 2021-01-18.
What conditions does trial NCT04683926 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT04683926?
The interventions under investigation include: Desmetramadol (DRUG).
Who is sponsoring clinical trial NCT04683926?
This trial is sponsored by Syntrix Biosystems, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04683926 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04683926's enrollment target sits among peer trials
24 325th of 374 higher than 42 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI